CRL Earnings & Financial Statements
Charles River Laboratories International, Inc.
$302.00
+$2.98(+1.00%)
60
Overall
60
Value
66
Tech
55
Quality
Market Cap
$14.27B
Volume
941.28K
52W Range
$146.20 - $333.30
Target Price
$317.44
CRL earnings and financial statements: Charles River Laboratories International, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CRL Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Cost of revenue | $2.69B | $2.72B | $2.63B | $2.51B | $2.21B |
| Operating income | $25.16M | $227.35M | $617.26M | $650.98M | $589.86M |
| EBITDA | $410.84M | $581.14M | $1.03B | $986.15M | $820.16M |
| Net income | -$144.34M | $22.20M | $474.62M | $486.23M | $390.98M |
| EPS (diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B |
| Total liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B |
| Shareholders’ equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B |
| Cash and equivalents | $213.77M | $194.61M | $276.77M | $233.91M | $241.21M |
| Long-term debt | $2.57B | $2.72B | $3.07B | $3.10B | $2.92B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $737.65M | $734.58M | $683.90M | $619.64M | $760.80M |
| Capital expenditure | -$219.15M | -$232.97M | -$318.53M | -$324.73M | -$228.77M |
| Free cash flow | $518.49M | $501.61M | $365.37M | $294.91M | $532.03M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CRL | $302.00 | +1.0% | 941.28K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Charles River Laboratories International, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW